Production (Stage)
Barinthus Biotherapeutics plc
BRNS
$0.654
-$0.156-19.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 14.97M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 14.97M | -- | -- |
| Cost of Revenue | 7.96M | 69.00K | 394.00K | 505.00K | 10.74M |
| Gross Profit | -7.96M | -69.00K | 14.58M | -505.00K | -10.74M |
| SG&A Expenses | 12.97M | -3.37M | 13.80M | 7.20M | 6.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -29.00K | -184.00K | -210.00K | -577.00K | -5.00K |
| Total Operating Expenses | 20.60M | 2.67M | 24.12M | 17.59M | 16.52M |
| Operating Income | -20.60M | -2.67M | -9.15M | -17.59M | -16.52M |
| Income Before Tax | -19.68M | -20.59M | -8.13M | -16.95M | -15.56M |
| Income Tax Expenses | -22.00K | 3.00K | -3.00K | -7.00K | -37.00K |
| Earnings from Continuing Operations | -19.66M | -20.59M | -8.13M | -16.94M | -15.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 10.00K | 51.00K | 15.00K | 12.00K | 31.00K |
| Net Income | -19.65M | -20.54M | -8.11M | -16.93M | -15.49M |
| EBIT | -20.60M | -2.67M | -9.15M | -17.59M | -16.52M |
| EBITDA | -19.36M | -2.04M | -8.48M | -16.93M | -15.89M |
| EPS Basic | -0.49 | -0.51 | -0.21 | -0.43 | -0.40 |
| Normalized Basic EPS | -0.31 | -0.03 | -0.13 | -0.27 | -0.25 |
| EPS Diluted | -0.49 | -0.51 | -0.21 | -0.43 | -0.40 |
| Normalized Diluted EPS | -0.31 | -0.03 | -0.13 | -0.27 | -0.25 |
| Average Basic Shares Outstanding | 40.27M | 40.16M | 39.42M | 39.04M | 38.77M |
| Average Diluted Shares Outstanding | 40.27M | 40.16M | 39.42M | 39.04M | 38.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |